MedTrace Logo

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

NCT06509958 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-10-30

No results posted yet for this study

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee arthroplasty compared with ropivacaine.

Conditions

  • Postoperative Pain Management in Total Knee Arthroplasty

Interventions

DRUG

HR18034

HR18034

DRUG

Ropivacaine Hydrochloride Injection

Ropivacaine Hydrochloride Injection

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-20
Primary Completion
2024-10-10
Completion
2024-10-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06509958 on ClinicalTrials.gov